FDA reported possible link between sibutramine, adverse events

February 2010
Cardiology Today;Feb2010, Vol. 13 Issue 2, p11
The article reports on a notice issued by the U.S. Food and Drug Administration (FDA) to health care professionals suggesting that a review of additional data on sibutramine indicated an increased risk for myocardial infarction (MI) and stroke in patients with a history of cardiovascular disease.


Related Articles

  • Obesity drug licence suspended. Praities, Nigel // Pulse;1/27/2010, Vol. 70 Issue 2, p4 

    The article reports on the suspension of the drug licence of obesity drug sibutramine by the European Medicines Agency (EMEA) due to cardiovascular disease (CVD) risk.

  • FDA reported possible link between sibutramine, adverse CV events.  // Endocrine Today;Feb2010, Vol. 8 Issue 2, p37 

    The article reports on the warning issued by the Food and Drug Administration (FDA) that sibutramine might be linked with adverse cardiovascular events.

  • Sibutramine on Cardiovascular Outcome. SCHEEN, ANDRE J. // Diabetes Care;May2011 Supplement 2, Vol. 34, pS114 

    The article offers a discussion on the perceived cardiovascular disease (CVD) risks of sibutramine and cardiovascular outcomes in overweight/obese patients with or without type 2 diabetes. Considered effective in managing obese patients, sibutramine improves insulin resistance markers, glucose...

  • Pharmacotherapy of Childhood Obesity. Freemark, Michael // Diabetes Care;Feb2007, Vol. 30 Issue 2, p395 

    The article presents an analysis of the benefits of lifestyle intervention and pharmacotherapy to the treatment of obesity in adults and children. It cites the role of biological factors in the difficulty of losing weight. Several placebo-controlled studies performed in obese adults showed that...

  • Drug Treatment for Obesity in the Post-Sibutramine Era. Cheung, Bernard M. Y. // Drug Safety;2011, Vol. 34 Issue 8, p641 

    Obesity is a major health problem worldwide. It is associated with cardiovascular diseases, diabetes mellitus and decreased longevity. In managing obesity, diet and exercise are essential; pharmacological therapy may be added for obese patients or overweight patients with cardiovascular risk...

  • Safety Assessment of an Anti-Obesity Drug (Sibutramine). Tyczynski, Jerzy E.; Oleske, Denise M.; Klingman, David; Ferrufino, Cheryl P.; Won Chan Lee // Drug Safety;8/1/2012, Vol. 35 Issue 8, p629 

    Background: Obesity is a serious and rapidly growing health problem worldwide. Few therapies are available beyond diet, exercise and bariatric surgery. A previously approved medication, sibutramine, has been withdrawn from the market due to concerns over the potential of increased risk of...

  • Cardiovascular Risk-Benefit Profile of Sibutramine. Scheen, A. J. // American Journal of Cardiovascular Drugs;2010, Vol. 10 Issue 5, p321 

    Sibutramine is a combined norepinephrine and serotonin reuptake inhibitor used as an antiobesity agent to reduce appetite and promote weight loss in combination with diet and exercise. At a daily dose of 10-20 mg, it was initially considered to have a good safety profile, as it does not induce...

  • Pharmacological Treatments for Obesity. Masuo, Kazuko; Esler, Murray D.; Lambert, Gavin W. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Jun2010, Vol. 10 Issue 2, p44 

    No abstract available.

  • Sibutramine.  // Reactions Weekly;5/15/2010, Issue 1301, p45 

    The article describes the case of a 46-year-old suffering from obesity who experienced an exacerbation of previously undetected variegate porphyria while receiving sibutramine treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics